|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





* Department of Dermatology, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH 44106;
Department of Dermatology, University of Yamanashi, Faculty of Medicine, Nakakoma, Japan;
Department of Dermatology, University of Szeged, Szeged, Hungary;
Department of Dermatology, Kyoto University, Graduate School of Medicine, Kyoto, Japan; and
¶
Department of Dermatology, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106
The balance between regulatory and effector functions is important for maintaining efficient immune responses, while avoiding autoimmunity. The inflammatory skin disease psoriasis is sustained by the ongoing activation of pathogenic effector T cells. We found that a CD4+ T lymphocyte subpopulation in peripheral blood, phenotypically CD25high, CTLA-4+, Foxp3high (regulatory T (Treg) cells), is deficient in its suppressor activity in psoriasis. This was associated with accelerated proliferation of CD4+ responder T cells in psoriasis, the majority of which expressed CXCR3. Nevertheless, criss-cross experiments isolated the defect to psoriatic Treg cells. To examine Treg cells in a nonlymphoid tissue of a human T cell-mediated disease, Treg cells were also analyzed and isolated from the site of inflammation, psoriatic lesional skin. At the regulatory vs effector T cells ratios calculated to be present in skin, however, the psoriatic Treg cell population demonstrated decreased suppression of effector T cells. Thus, dysfunctional blood and target tissue CD4+CD25high Treg cell activity may lead to reduced restraint and consequent hyperproliferation of psoriatic pathogenic T cells in vivo. These findings represent a critical component of human organ-specific autoimmune disease and may have important implications with regard to the possible therapeutic manipulation of Treg cells in vivo.
This article has been cited by other articles:
![]() |
D. Q. Tran, H. Ramsey, and E. M. Shevach Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-{beta} dependent but does not confer a regulatory phenotype Blood, October 15, 2007; 110(8): 2983 - 2990. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Hubert, N. Jacobs, J.-H. Caberg, J. Boniver, and P. Delvenne The cross-talk between dendritic and regulatory T cells: good or evil? J. Leukoc. Biol., October 1, 2007; 82(4): 781 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sasaki, H. Ikeda, S. Sawada, Y. Sato, and Y. Nakanuma Naturally-occurring regulatory T cells are increased in inflamed portal tracts with cholangiopathy in primary biliary cirrhosis J. Clin. Pathol., October 1, 2007; 60(10): 1102 - 1107. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. STENDERUP, C. ROSADA, A. WORSAAE, J. T. CLAUSEN, and T. NORMAN DAM Interleukin-20 as a Target in Psoriasis Treatment Ann. N.Y. Acad. Sci., September 1, 2007; 1110(1): 368 - 381. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. J. de Boer, C. M. van der Loos, P. Teeling, A. C. van der Wal, and M. B.M. Teunissen Immunohistochemical Analysis of Regulatory T Cell Markers FOXP3 and GITR on CD4+CD25+ T Cells in Normal Skin and Inflammatory Dermatoses J. Histochem. Cytochem., September 1, 2007; 55(9): 891 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Haas, B. Fritzsching, P. Trubswetter, M. Korporal, L. Milkova, B. Fritz, D. Vobis, P. H. Krammer, E. Suri-Payer, and B. Wildemann Prevalence of Newly Generated Naive Regulatory T Cells (Treg) Is Critical for Treg Suppressive Function and Determines Treg Dysfunction in Multiple Sclerosis J. Immunol., July 15, 2007; 179(2): 1322 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Leon, N. Contractor, I. Fuss, T. Marth, E. Lahey, S. Iwaki, A. la Sala, V. Hoffmann, W. Strober, and B. L. Kelsall Antibodies to Complement Receptor 3 Treat Established Inflammation in Murine Models of Colitis and a Novel Model of Psoriasiform Dermatitis J. Immunol., November 15, 2006; 177(10): 6974 - 6982. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hirahara, L. Liu, R. A. Clark, K.-i. Yamanaka, R. C. Fuhlbrigge, and T. S. Kupper The Majority of Human Peripheral Blood CD4+CD25highFoxp3+ Regulatory T Cells Bear Functional Skin-Homing Receptors J. Immunol., October 1, 2006; 177(7): 4488 - 4494. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Toichi, G. Torres, T. S. McCormick, T. Chang, M. A. Mascelli, C. L. Kauffman, N. Aria, A. B. Gottlieb, D. E. Everitt, B. Frederick, et al. An Anti-IL-12p40 Antibody Down-Regulates Type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis J. Immunol., October 1, 2006; 177(7): 4917 - 4926. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Loser and S. Beissert Therapeutic modulation of cutaneous autoimmunity by regulatory T cells Rheumatology, October 1, 2006; 45(suppl_3): iii20 - iii22. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wei, I. Kryczek, and W. Zou Regulatory T-cell compartmentalization and trafficking Blood, July 15, 2006; 108(2): 426 - 431. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Seddiki, B. Santner-Nanan, J. Martinson, J. Zaunders, S. Sasson, A. Landay, M. Solomon, W. Selby, S. I. Alexander, R. Nanan, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells J. Exp. Med., July 10, 2006; 203(7): 1693 - 1700. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Saitoh and Y. Nagayama Regulation of Graves' Hyperthyroidism with Naturally Occurring CD4+CD25+ Regulatory T Cells in a Mouse Model Endocrinology, May 1, 2006; 147(5): 2417 - 2422. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Longhi, M. J. Hussain, R. R. Mitry, S. K. Arora, G. Mieli-Vergani, D. Vergani, and Y. Ma Functional Study of CD4+CD25+ Regulatory T Cells in Health and Autoimmune Hepatitis J. Immunol., April 1, 2006; 176(7): 4484 - 4491. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Miyara, Z. Amoura, C. Parizot, C. Badoual, K. Dorgham, S. Trad, M. Kambouchner, D. Valeyre, C. Chapelon-Abric, P. Debre, et al. The immune paradox of sarcoidosis and regulatory T cells J. Exp. Med., February 21, 2006; 203(2): 359 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Miyara, Z. Amoura, C. Parizot, C. Badoual, K. Dorgham, S. Trad, D. Nochy, P. Debre, J.-C. Piette, and G. Gorochov Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus J. Immunol., December 15, 2005; 175(12): 8392 - 8400. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Madariaga, L. Naldi, L. Chatenoud, S. Khan, M. P. Schon, and W.-H. Boehncke Psoriasis N. Engl. J. Med., August 25, 2005; 353(8): 848 - 850. [Full Text] [PDF] |
||||
![]() |
O. PARK, I. GRISHINA, P. S. LEUNG, M E. GERSHWIN, and T PRINDIVILLE Analysis of the Foxp3/Scurfin Gene in Crohn's Disease Ann. N.Y. Acad. Sci., June 1, 2005; 1051(1): 218 - 228. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |